Eating Disorders-Exercise 2015-2020


*Articles/Studies in Pre-2000 List
+Articles/Studies in 2000-2009 List
^Articles/Studies in 2010-2014 List
>Information in Another Section

>EHLERS-DANLOS SYNDROME+ (See News Articles 2010-2018)
ENDOTOXEMIA (Low-grade inflammation from circulating endotoxins)

ESSENTIAL TREMOR (See Also News Articles 2010-2018)

A behavioral and pharmacological characterization of palatable diet alternation in mice. (USA) (full – 2017)
Effects of a Weight Loss Program on Metabolic Syndrome, Eating Disorders and Psychological Outcomes: Mediation by Endocannabinoids. (Switzerland) (full – 2018)
Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies. (Canada/ USA) (abst – 2018)
Cigarette smoke during lactation in rat female progeny: Late effects on endocannabinoid and dopaminergic systems. (Brazil) (abst – 2019)

Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis. (USA) (full – 2015)
Cannabidiol: a potential treatment for post Ebola syndrome? (USA) (full – 2016)
Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges. (Hungary) (full – 2017)

Decreased circulating anandamide levels in preeclampsia. (USA) (link to download– 2015)
[268-POS]: Placental expression of the endocannabinoid system in preeclampsia. (Hungary) (abst – 2015)
A case of cannabinoid hyperemesis syndrome with heliobacter pylori and pre-eclampsia during pregnancy. (USA) (abst – 2017)

Cannabis and Dr Piffard-A Century Ahead of the Curve. (USA) (abst – 2016)
The Endocannabinoid System and Its Role in Eczematous Dermatoses. (USA) (abst – 2017)
Echinacea purpurea-derived alkylamides exhibit potent anti-inflammatory effects and alleviate clinical symptoms of atopic eczema. (Hungary/ Germany) (abst – 2017)
Common Allergens Prevalent in and Around Ambala, Haryana: An Intradermal Study among Patients with Asthma and Allergic Rhinitis and Atopic Dermatitis. (India) (full – 2018)
Cannabinoids for the Treatment of Chronic Pruritus: A Review. (USA) (abst – 2020)

Changes in cannabinoid receptors, aquaporin 4 and vimentin expression after traumatic brain injury in adolescent male mice. Association with edema and neurological deficit. (Spain/ Germany) (full – 2015)
A Cannabinoid Receptor 2 Agonist Prevents Thrombin-Induced Blood-Brain Barrier Damage via the Inhibition of Microglial Activation and Matrix Metalloproteinase Expression in Rats. (China) (link to PDF – 2015)
Minocycline Attenuates Neonatal Germinal-Matrix-Hemorrhage-Induced Neuroinflammation and Brain Edema by Activating Cannabinoid Receptor 2 (China) (link to PDF–2015) Cannabinoid CB2 receptor stimulation attenuates brain edema and neurological deficits in a germinal matrix hemorrhage rat model. (China) (link to download – 2015) Cannabinoid receptor 2 attenuates microglial accumulation and brain injury following germinal matrix hemorrhage via ERK dephosphorylation in vivo and in vitro. (China) (abst – 2015)
Cannabinoid Receptor Type 2 Agonist Attenuates Acute Neurogenic Pulmonary Edema by Preventing Neutrophil Migration after Subarachnoid Hemorrhage in Rats. (China) (abst – 2015)
Mustard vesicants alter expression of the endocannabinoid system in mouse skin. (USA) (full – 2016)
Activation of Cannabinoid Receptor 2 Attenuates Mechanical Allodynia and Neuroinflammatory Responses in a Chronic Post-Ischemic Pain Model of Complex Regional Pain Syndrome Type I in Rats. (USA/ China) (click “Alternate Sources”, then “rsdsorg” for download – 2016)
Cannabinoid Receptor Type 2 Agonist Attenuates Acute Neurogenic Pulmonary Edema by Preventing Neutrophil Migration after Subarachnoid Hemorrhage in Rats . (USA/ Japan) (abst – 2016)
Selective modulator of cannabinoid receptor type 2 reduces memory impairment and infarct size during cerebral hypoperfusion and vascular dementia. (India) (abst – 2016)
Selective modulator of cannabinoid receptor type 2 (CB2) against biochemical alterations and brain damage in chronic cerebral hypoperfusion induced vascular dementia. (India) (abst – 2016)
Endocannabinoids: A Promising Impact for Traumatic Brain Injury. (USA) (full – 2017)

Inflammatory Regulation by Driving Microglial M2 Polarization: Neuroprotective Effects of Cannabinoid Receptor-2 Activation in Intracerebral Hemorrhage. (China) (full – 2017)
Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization. (USA/ Italy) (full – 2017)
An endocannabinoid uptake inhibitor from black pepper exerts pronounced anti- inflammatory effects in mice. (Mexico/ Switzerland) (link to PDF– 2017)
Photobiomodulation Therapy Improves Acute Inflammatory Response in Mice: the Role of Cannabinoid Receptors/ATP-Sensitive K+ Channel/p38-MAPK Signalling Pathway. (Brazil) (link to PDF – 2017)
Bilateral multiple exudative retinal detachments and macular edema in a patient diagnosed with synthetic cannabinoid (Bonzai) intoxication. (Turkey) (link to PDF – 2017)
AB-CHMINACA-induced sudden death from non-cardiogenic pulmonary edema. (Japan) (abst – 2017)
Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury. (USA) (full – 2018)
The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors. (Mexico/ Switzerland) (full – 2018)
Cannabinoid receptor 2 agonist attenuates blood-brain barrier damage in a rat model of intracerebral hemorrhage by activating the Rac1 pathway. (China) (link to PDF – 2018)
Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain. (Canada) (link to PDF – 2018) Monoacylglycerol Lipase Inhibitor is Safe when Combined with Delayed r-tPA Administration in Treatment of Stroke. (Iran) (click “rumsacir” for download – 2018)
A cannabinoid receptor 2 agonist reduces blood-brain barrier damage via induction of MKP-1 after intracerebral hemorrhage in rats. (China) (abst 2018)
JZL184, as a monoacylglycerol lipase inhibitor, down-regulates inflammation in a cannabinoid pathway dependent manner. (Iran) (abst – 2018)
Clinical effects of reported synthetic cannabinoid exposure in patients admitted to the intensive care unit. (USA) (abst – 2018)
Cannabidiol As A Novel Therapeutic Strategy For Oral Inflammatory Diseases: A Review Of Current Knowledge And Future Perspectives. (Czech Republic) (abst – 2019)

Endocannabinoid CB1 receptors are involved in antiepileptogenic effect of low frequency electrical stimulation during perforant path kindling in rats (Iran – abst–2018)

 Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study. (Germany) (abst – 2017) Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study. (Germany/ Sweden/ UK) (link to download – 2018)

Fetal Alcohol Spectrum Disorder: Potential Role of Endocannabinoids Signaling. (USA) (full – 2015)
Preferential epithelial expression of type-1 cannabinoid receptor (CB1R) in the developing canine embryo. (Italy) (full – 2015)
Endocannabinoid signaling in female reproductive events: a potential therapeutic target? (Italy) (full – 2015)
Gestation Related Gene Expression of the Endocannabinoid Pathway in Rat Placenta. (Australia) (full – 2015)
Cannabinoid Receptor-2 Regulates Embryonic Hematopoietic Stem Cell Development via PGE2 and P-selectin Activity. (USA) (full – 2015)
Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture. (Sweden/ Poland/ Austria/ Italy) (full – 2015)
Use of paracetamol during pregnancy and child neurological development. (Belgium) (full – 2015)
Dynamics of expression and localization of the cannabinoid system in granulosa cells during oocyte nuclear maturation. (Spain) (full – 2015)
Role of the endocannabinoid system in the mechanisms involved in the LPS-induced preterm labor. (Argentina) (full – 2015)
Epigenetic Effects of Cannabis Exposure. (USA) (full – 2015)
cnrip1 is a regulator of eye and neural development in Xenopus laevis. (Japan) (full – 20 15)
Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice. (USA) (full – 2015)
Lipid abundance in zebrafish embryos is regulated by complementary actions of the Endocannabinoid System and Retinoic Acid Pathway. (Australia) (full – 2015)
Marijuana use and pregnancy: prevalence, associated characteristics, and birth outcomes. (USA) (link to PDF – 2015)
Progesterone and anandamide in pregnancy loss. (Argentina/ USA) (download – 2015)
Long-term consequences of perinatal and adolescent cannabinoid exposure on neural and psychological processes. (Spain) (click “researchgate” for download – 2015) 0&as_vis=1&oi=scholart
Anandamide restricts uterine stromal differentiation and is critical for complete decidualization. (Portugal) (abst – 2015)

Anandamide and Decidual Remodeling: COX-2 oxidative metabolism as a key regulator. (Portugal) (abst – 2015)
The endocannabinoid 2-arachidonoylglycerol dysregulates the synthesis of proteins by the human syncytiotrophoblast. (Portugal) (abst – 2015)
Maternal Caloric Restriction Implemented during the Preconceptional and Pregnancy Period Alters Hypothalamic and Hippocampal Endocannabinoid Levels at Birth and Induces Overweight and Increased Adiposity at Adulthood in Male Rat Offspring. (Spain/ Germany) (full – 2016)
Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid. (Italy) (full – 2016)
Nutritional n-3 PUFA Deficiency Abolishes Endocannabinoid Gating of Hippocampal Long-Term Potentiation. (France) (full – 2016)
Exocannabinoids effect on in vitro bovine oocyte maturation via activation of AKT and ERK1/2. (Spain/ Colombia) (full – 2016)
Sexually-dimorphic alterations in cannabinoid receptor density depend upon prenatal/early postnatal history. (USA) (full – 2016)
A role for the endocannabinoid system in premature luteal regression and progesterone withdrawal in lipopolysaccharide-induced early pregnancy loss model. (Argentina) (full – 2016)
Exposure to a Highly Caloric Palatable Diet during the Perinatal Period Affects the Expression of the Endogenous Cannabinoid System in the Brain, Liver and Adipose Tissue of Adult Rat Offspring. (Spain) (full – 2016)
Conceptus development and transcriptome at preimplantation stages in lactating dairy cows of distinct genetic groups and estrous cyclic statuses. (USA) (full – 2016)
Dynamic of expression and localization of cannabinoid-degrading enzymes FAAH and MGLL in relation to CB1 during meiotic maturation of human oocytes. (Spain) (abst – 2016)
The endocannabinoid system: an emergent player in human placentation. (Portugal) (abst – 2016)
Endocannabinoids participate in placental apoptosis induced by hypoxia inducible factor- 1. (Argentina) (abst – 2016)
Peripheral Blood Mononuclear Cells Infiltration Downregulates Decidual FAAH Activity in an LPS-Induced Embryo Resorption Model. (Argentina) (abst – 2016)
Fetal Syndrome of Endocannabinoid Deficiency (FSECD) In Maternal Obesity. (USA) (abst – 2016)
Formation of OX-1R/CB1R heteromeric complexes in embryonic mouse hypothalamic cells: Effect on intracellular calcium, 2-arachidonoyl-glycerol biosynthesis and ERK phosphorylation. (Italy/ Germany) (abst – 2016) Alcohol, Methamphetamine, and Marijuana Exposure Have Distinct Effects on the Human Placenta. (USA/ South Africa) (abst – 2016)
Immunohistochemistry Detected and Localized Cannabinoid Receptor Type 2 in Bovine Fetal Pancreas at Late Gestation. (Italy) (full – 2017)
A Putative ‘Pre-Nervous’ Endocannabinoid System in Early Echinoderm Development. (USA/ Russia) (full – 2017)
Activation of Both CB1 and CB2 Endocannabinoid Receptors Is Critical for Masculinization of the Developing Medial Amygdala and Juvenile Social Play Behavior. (USA) (full – 2017)
Overactive type 2 cannabinoid receptor induces meiosis in fetal gonads and impairs ovarian reserve. (Italy) (full – 2017)
The Cannabinoid Receptor Interacting Proteins 1 of zebrafish are not required for morphological development, viability or fertility. (UK) (full – 2017)
The Roles of Anandamide, Fatty Acid Amide Hydrolase, and Leukemia Inhibitory Factor on the Endometrium during the Implantation Window. (China) (full – 2017)
Suppression of STAT3 Signaling by Δ9-Tetrahydrocannabinol (THC) Induces Trophoblast Dysfunction. (China) (full – 2017)
Evidence for CB2 receptor involvement in LPS-induced reduction of cAMP intracellular levels in uterine explants from pregnant mice: pathophysiological implications. (Argentina) (full – 2017)
Role of the endocannabinoid system in vertebrates: Emphasis on the zebrafish model. (USA) (full – 2017)
Maternal alcohol exposure during mid-pregnancy dilates fetal cerebral arteries via endocannabinoid receptors. (USA) (full – 2017)
Cannabis use by women during pregnancy does not influence infant DNA methylation of the dopamine receptor DRD4. (Australia/ France) (full – 2017)
Adolescent Female Cannabinoid Exposure Diminishes the Reward-Facilitating Effects of Δ9-Tetrahydrocannabinol and d-Amphetamine in the Adult Male Offspring. (Greece/ USA) (full – 2017)
THC Treatment Alters Glutamate Receptor Gene Expression in Human Stem Cell- Derived Neurons. (USA) (full – 2017)
Cannabis Use during Pregnancy: Pharmacokinetics and Effects on Child Development. (USA) (full – 2017)
Metformin attenuates susceptibility to inflammation-induced preterm birth in mice with higher endocannabinoid levels. (USA) (full – 2017)
Developmental effects of cannabidiol and Δ9-tetrahydrocannabinol in zebrafish. (USA) (full – 2017)
HDAC1 and HDAC3 Underlie Dynamic H3K9 Acetylation During Embryonic Neurogenesis and in Schizophrenia-like Animals. (Czech Republic/ Netherlands/ Austria/ Israel/ Italy) (link to PDF – 2017)
CB1 cannabinoid receptor drives oocyte maturation and embryo development via PI3K/Akt and MAPK pathways. (Spain/ Columbia) (link to PDF – 2017)
The endocannabinoid system expression in the female reproductive tract is modulated by estrogen (Portugal) (link to PDF – 2017)
What effects—if any—does marijuana use during pregnancy have on the fetus or child? (USA) (click “umsystemedu” for download – 2017)
Maternal Cannabinoid Use Alters Cannabinoid (CB1) and Endothelin (ETB) Receptor Expression in the Brains of Dams but Not Their Offspring. (USA) (abst – 2017)
Interpretation of cannabis findings in the hair of very young children: mission impossible. (France) (abst – 2017)
The synthetic cannabinoid WIN-55,212-55,212 induced-apoptosis in cytotrophoblasts cells by a mechanism dependent on CB1 receptor. (Portugal) (abst – 2017)
Neuro-glial cannabinoid receptors modulate signaling in the embryonic avian retina. (Brazil) (full – 2018)
Cannabinoid Receptor Type 1 Expression in the Developing Avian Retina: Morphological and Functional Correlation With the Dopaminergic System. (Brazil) (full – 2018)
Motor neuron development in zebrafish is altered by brief (5-hr) exposures to THC (∆9- tetrahydrocannabinol) or CBD (cannabidiol) during gastrulation. (Canada) (full – 2018)
Marijuana Use During Pregnancy and Breastfeeding: Implications for Neonatal and Childhood Outcomes. (USA) (full – 2018)
Sex Difference: What does cannabis do to the brain before birth? (Switzerland) (full – 2018)
A cannabinoid receptor type 1 (CB1R) agonist enhance the developmental neurotoxicity of acetaminophen (paracetamol). (Sweden) (full – 2018)
Transcriptomic Characterization of the Human Habenula Highlights Drug Metabolism and the Neuroimmune System. (Canada/ USA) (full – 2018)
Sex-dependent effects of in utero cannabinoid exposure on cortical function. (France/ USA) (full – 2018)
Altered brain cannabinoid 1 receptor mRNA expression across postnatal development in the MAM model of schizophrenia. (USA) (full – 2018)
Sex specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signaling. (Italy) (full – 2018)
Additive drug-specific and sex-specific risks associated with co-use of marijuana and tobacco during pregnancy: Evidence from 3 recent developmental cohorts (2003-2015). (USA) (full – 2018)
Psychological Functioning of Women Taking Illicit Drugs during Pregnancy and the Growth and Development of Their Offspring in Early Childhood. (USA) (full – 2018)
Prenatal tobacco and marijuana co-use: Impact on newborn neurobehavior. (USA) (full – 2018)
An epidemiological, developmental and clinical overview of cannabis use during pregnancy. (Netherlands/ Norway/ USA) (full – 2018)
Drug Use during Pregnancy and its Consequences: A Nested Case Control Study on Severe Maternal Morbidity. (Brazil) (full in English, abst in Portuguese – 2018)
Maternal and paternal cannabis use during pregnancy and the risk of psychotic-like experiences in the offspring. (Netherlands/ USA) (link to PDF – 2018) Marijuana use during and after pregnancy and association of prenatal use on birth outcomes: A population-based study. (USA) (link to PDF – 2018)
Endocannabinoid Signaling in Embryonic Neuronal Motility and Cell–Cell Contact – Role of mGluR5 and TRPC3 Channels. (Finland) (click “helsinkifi” for download – 2018)
Analysis of the Uptake, Metabolism, and Behavioral Effects of Cannabinoids on Zebrafish Larvae. (Canada) (click “Open Access”, then “nrcpublicationscanadaca” for download–2018)
A Modern Conundrum for the Pediatrician: The Safety of Breast Milk and the Cannabis- Using Mother. (USA) (article – 2018)
Evaluation of Bisphenol A influence on endocannabinoid system in pregnant women. (Poland) (abst – 2018)
CatSper: A Unique Calcium Channel of the Sperm Flagellum. (USA) (abst – 2018)
Developmental and behavioral effects in neonatal and adult mice following prenatal activation of endocannabinoid receptors by capsaicin. (USA) (abst – 2018)
Effect of chronic THC administration in the reproductive organs of male mice, spermatozoa and in vitro fertilization. (Spain/ Columbia ) (abst – 2018)
Effects of feeding a source of omega-3 fatty acid during the early postpartum period on the endocannabinoid system in the bovine endometrium. (Iran) (abst – 2018)
Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos. (Brazil) (abst – 2018)
Gestational Age-Dependent Interplay between Endocannabinoid Receptors and Alcohol in Fetal Cerebral Arteries. (USA) (full – 2019)
Tetrahydrocannabinol Modulates in Vitro Maturation of Oocytes and Improves the Blastocyst Rates after in Vitro Fertilization. (Spain/ Colombia) (full – 2019)
Ontogeny and programming of the fetal temporal cortical endocannabinoid system by moderate maternal nutrient reduction in baboons (Papio spp.). (USA) (full – 2019)
Developmental and reproductive toxicity studies of BIA 10-2474. (USA/ Switzerland) (full–2019)
Life-long epigenetic programming of cortical architecture by maternal ‘Western’ diet during pregnancy. (Austria/ UK/ Germany/France/ Italy/ Hungary/ Japan/ Canada/ USA/ Sweden) (link to PDF– 2019)
Adverse outcome pathway of developmental neurotoxicity resulting from prenatal exposures to cannabis contaminated with organophosphate pesticide residues. (USA) (link to PDF – 2019)
Docosahexaenoic acid,22:6n-3: its roles in the structure and function of the brain. (India/ Finland/ Norway) (link to PDF – 2019)
Marijuana Use in Pregnancy: An Updated Look at Marijuana Use and Its Impact on Pregnancy. (USA) (click “uswracir” for download – 2019)
Multigenerational consequences of early-life cannabinoid exposure in zebrafish. (USA) (abst – 2019) Ethanol and cannabinoids interact to alter behavior in a zebrafish fetal alcohol spectrum disorder model. (USA) (abst – 2019)
Assessing the acute effects of prenatal synthetic cannabinoid exposure on murine fetal brain vasculature using optical coherence tomography. (USA) (abst – 2019)
Herring roe oil supplementation alters microglial cell gene expression and reduces peripheral inflammation after immune activation in a neonatal piglet model (USA) (abst–2019)
Maternal high-fat diet impairs leptin signaling and up-regulates type-1 cannabinoid receptor with sex-specific epigenetic changes in the hypothalamus of newborn rats. (Brazil/ USA) (abst – 2019)
Mice Missing Cnr1 and Cnr2 Show Implantation Defects. (USA) (abst – 2019)
Synthetic cannabinoids and their impact on neurodevelopmental processes. (Portugal) (abst – 2019)
Health care experiences and birth outcomes: Results of an Aboriginal birth cohort. (Australia) (abst – 2019)
The effect of high maternal linoleic acid on endocannabinoid signalling in rodent hearts. (Australia) (abst – 2019)
Early Exposure to THC Alters M-Cell Development in Zebrafish Embryos. (Canada) (full – 2020)
Recreational Cannabis Legalization in the US and Maternal Use during the Preconception, Prenatal, and Postpartum Periods. (USA) (full – 2020)
Focus on the endocannabinoid system and the reprotoxicity of marijuana in female users. (France) (abst in French & English – 2020)

Anti-N-methyl-D-aspartate receptor encephalitis and drug abuse – the probable role of molecular mimicry or the overstimulation of CB receptors in a 17-year-old adolescent – case report. (Hungary) (download – 2016)

Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells. (Israel/ USA) (full – 2015)
A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis. (Italy) (full – 2015)
Activation of Cannabinoid CB2 receptors Reduces Hyperalgesia in an Experimental Autoimmune Encephalomyelitis Mouse Model of Multiple Sclerosis. (USA) (full – 2015)
Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis. (Italy) (link to PDF – 2015)
Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. (UK) (link to PDF – 2015) essive_Multiple_Sclerosis_by_Cannabis-Based_Cannabinoids
HU-446 and HU-465, derivatives of the non-psychoactive cannabinoid cannabidiol, decrease the activation of encephalitogenic T cells. (Israel/ India) (link to download–2015)
Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. (Iran) (click “READ THE FULL ARTICLE” for download–2015)
Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis. (USA) (abst – 2015)
Neuroprotective Effect Is Driven Through the Upregulation of CB1 Receptor in Experimental Autoimmune Encephalomyelitis. (China) (abst – 2015)
The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ(9)- tetrahydrocannabinol acting through CB1 receptors. (Spain) (abst – 2015)
Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells. (Israel/ USA) (full – 2016)
Interaction between interleukin-1β and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis. (Italy/ Germany) (full – 2016)
Development and Pharmacological Characterization of Selective Blockers of 2- Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. (Italy/ France/ USA) (full – 2016)
Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. (Italy) (click “orvosikannabiszcom” for download – 20 16)
WWL70 attenuates PGE2 production derived from 2-arachidonoylglycerol in microglia by ABHD6-independent mechanism. (USA) (full – 2017)
Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid. (Israel) (full – 2017)

(-)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis. (Brazil) (full – 2017)
The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases . (Italy) (full – 2017)
Chapter 4 Neuropathic Pain in Multiple Sclerosis—Current Therapeutic Intervention and Future Treatment Perspectives. (USA) (full – 2017)
Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis. (China/ Australia) (click “uswracir” for download – 2017)
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients (Italy) (abst – 2017)
Interferon-γ causes mood abnormalities by altering cannabinoid CB1 receptor function in the mouse striatum. (Italy) (abst – 2017)
Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis. (Spain) (abst – 2017)
Managing neuropathic pain in multiple sclerosis: Pharmacological interventions. (Australia) (abst – 2017)
Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. (Spain/ USA/ Italy/ Germany) (full – 2018)
Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells. (USA) (full – 2018)
The inhibition of CB1 receptor accelerates the onset and development of EAE possibly by regulating microglia/macrophages polarization. (China) (abst – 2018)
Evaluation of Marijuana Compounds on Neuroimmune Endpoints in Experimental Autoimmune Encephalomyelitis. (USA) (abst – 2018)
Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice. (Israel) (abst – 2018)
Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. (USA) (abst – 2019)
Combination of Imipramine, a sphingomyelinase inhibitor, and β-caryophyllene improve their therapeutic effects on experimental autoimmune encephalomyelitis (EAE). (Iran) (abst – 2019) 

Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. (USA) (full – 2016)
The cannabinoid receptor CB1 contributes to the development of ectopic lesions in a mouse model of endometriosis. (Italy/ Spain) (full – 2016)
Elevated Systemic Levels of Endocannabinoids and Related Mediators Across the Menstrual Cycle in Women With Endometriosis. (Italy) (click “PDF Reader” for full–2016)
Cannabinoid receptor 1 contributes to sprouted innervation in endometrial ectopic growth through mitogen-activated protein kinase activation. (China) (click “PDF Reader” for full – 2016)
Anandamide interferes with human endometrial stromal-derived cell differentiation: An effect dependent on inhibition of cyclooxygenase-2 expression and prostaglandin E2 release. (Portugal) (abst – 2016)
The Clinical Significance of Endocannabinoids in Endometriosis Pain Management (Israel) (full – 2017)
Endocannabinoids modulate apoptosis in endometriosis and adenomyosis (Turkey) (link to PDF–2017)
From pathogenesis to clinical practice: Emerging medical treatments for endometriosis (Italy) (abst – 2018)
Endocannabinoids as endometrial inflammatory markers in lactating Holstein cows. (Iran/ Italy) (abst – 2018)
Self-management strategies amongst Australian women with endometriosis: a national online survey. (Australia) (full – 2019)
Decreased Expression of Cannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients with Adenomyosis. (China) (full – 2019)
Selective Action of N-Arachidonoyl Dopamine on Viability and Proliferation of Stromal Cells from Eutopic and Ectopic Endometrium. (abst – 2019)
Synthetic cannabinoids and endometrial stromal cell fate: Dissimilar effects of JWH-122, UR-144 and WIN55,212-2. (Portugal) (abst – 2019)
Anandamide targets aromatase: A breakthrough on human decidualization. (Portugal) (abst – 2019)
Self-Reported Efficacy of Cannabis for Endometriosis Pain. (USA) (abst – 2019)
Cannabis Use, a Self-Management Strategy Among Australian Women With Endometriosis: Results From a National Online Survey. (Australia) (abst – 2019)
The role of the endocannabinoid system in aetiopathogenesis of endometriosis: A potential therapeutic target. (Australia/ Switzerland) (abst – 2019)
Disease-modifying effects of natural Δ9-tetrahydrocannabinol in endometriosis- associated pain. (Spain) (full– 2020)

Metabolic endotoxemia affects about 33% of Americans Cannabinoid Receptor 2 Modulates Neutrophil Recruitment in a Murine Model of Endotoxemia. (UK) (full – 2017)
Low-fat yogurt consumption reduces biomarkers of chronic inflammation and inhibits markers of endotoxin exposure in healthy premenopausal women: a randomised controlled trial. (USA) (full in English & French – 2017) chronic-inflammation-and-inhibits-markers-of-endotoxin-exposure-in-healthy-premenopausal-women-a-randomised-controlled- trial/B7ED318F1F80DCC04DBC348700C071C1/core-reader
TLR4 Receptor Induces 2-AG–Dependent Tolerance to Lipopolysaccharide and Trafficking of CB2 Receptor in Mast Cells. (Mexico/ France) (abst – 2019)

Consuming energy drinks at the age of 14 predicted legal and illegal substance use at 16 (Switzerland) (abst–2016)
The role of energy drink consumption in the intention to initiate marijuana use among adolescents. (USA) (abst – 2019)

Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. (USA) (full – 2018) Dermatology-Related Uses of Medical Cannabis Promoted by Dispensaries in Canada, Europe, and the United States. (Canada) (abst – 2018)
Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases. (Netherlands) (full – 2019)

Augmented Inhibition from Cannabinoid-Sensitive Interneurons Diminishes CA1 Output after Traumatic Brain Injury. (USA) (full – 2015)
Muscarinic M1 receptor and cannabinoid CB1 receptor do not modulate paraoxon- induced seizures. (USA) (full – 2015)
Medicinal cannabis. (Australia) (full – 2015)


Cannabidiol Rescues Acute Hepatic Toxicity and Seizure Induced by Cocaine. (Brazil) (full – 2015)
Defects in fatty acid amide hydrolase 2 in a male with neurologic and psychiatric symptoms. (Canada/ USA) (full – 2015)
Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. (USA) (full – 2015)
Interaction between Cannabinoid Compounds and Capsazepine in Protection against Acute Pentylenetetrazole-induced Seizure in Mice. (Iran) (full – 2015)
Phytocannabinoids and epilepsy. (Brazil) (full – 2015)
Cannabinoids and Epilepsy. (Brazil) (full – 2015)
Impaired 2-AG signaling in hippocampal glutamatergic neurons: aggravation of anxiety- like behavior and unaltered seizure susceptibility. (Germany/ Australia) (full – 2015)
Cannabinoids: is there a potential treatment role in epilepsy? (USA) (full – 2015)
Loss of Either Rac1 or Rac3 GTPase Differentially Affects the Behavior of Mutant Mice and the Development of Functional GABAergic Networks. (Italy) (full – 2015)
TRPV1 Channel: A Potential Drug Target for Treating Epilepsy. (Turkey) (full – 2015)
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. (USA) (full – 2015)
Homer Protein-Metabotropic Glutamate Receptor Binding Regulates Endocannabinoid Signaling and Affects Hyperexcitability in a Mouse Model of Fragile X Syndrome. (USA) (full – 2015)
Enhancement of endocannabinoid signalling protects against cocaine-induced neurotoxicity. (Brazil) (full – 2015)
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. (USA) (full – 2015)
Marijuana: A Time-Honored but Untested Treatment for Epilepsy. (Canada) (full – 2015) time-honored-but-untested-treatment-for-epilepsydiv/DDEDDD9EAA09918D3D69CC7CA047AE5C/core-reader


Molecular Targets of Cannabidiol in Neurological Disorders. (UK) (full – 2015)
A New Differential Diagnosis: Synthetic Cannabinoids-Associated Acute Renal Failure. (USA) (full – 2015)
Marijuana Legalization: Impact on Physicians and Public Health. (USA) (full – 2015)
The basolateral amygdala γ-aminobutyric acidergic system in health and disease. (USA) (full – 2015)
Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: Study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat. (Italy) (full – 2015)
ACEA (a highly selective cannabinoid CB1 receptor agonist) stimulates hippocampal neurogenesis in mice treated with antiepileptic drugs. (Poland) (full – 2015)
The effects of adolescent cannabinoid exposure on seizure susceptibility and lethality in adult male rats. (USA) (full – 2015)
Options for pharmacoresistant epilepsy in children: when medications don’t work. (USA) (link to PDF – 2015)
Marijuana Use in Epilepsy: The Myth and the Reality. (USA) (link to PDF – 2015)
Cannabidiol as potential treatment in refractory pediatric epilepsy. (Italy) (link to PDF–2015)
The role of cannabinoids and leptin in neurological diseases. (Turkey) (link to PDF–2015)
Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy. (USA/ Japan) (link to PDF – 2015) epilepsy
Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report. (USA) (download – 2015)
Population Pharmacokinetic Model of THC Integrates Oral, Intravenous, and Pulmonary Dosing and Characterizes Short- and Long-term Pharmacokinetics. (Netherlands) (download – 2015)
An outbreak of acute delirium from exposure to the synthetic cannabinoid AB- CHMINACA. (USA) (link to download – 2015)
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. (USA) (click “researchgate” for download– 2015),5&as_vis=1&scioq=%22Cannabidiol+in+patients+with+treatment-resistant+epilepsy:+an+open-label+interventional+trial%22 Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. (USA) (click “semanticscholar” for download – 2015) Gastaut+syndrome.%22&btnG Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors. (Iran) (click “gumsacir” for download – 2015)
Changes over time of cannabinoid receptor 1 in hippocampus of status epilepticus rats (China) (abst in English – 2015)
(abst in Chinese – 2015)
Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs. (Russia) (abst – 2015)
Neuroprotective effects of trans-caryophyllene against kainic Acid induced seizure activity and oxidative stress in mice. (China) (abst – 2015)
Effects of WIN 55,212-2 (a synthetic cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant activity of various novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice. (Poland) (abst – 2015)
Issues and promise in clinical studies of botanicals with anticonvulsant potential. (Israel) (abst– 2015)
A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA. (USA) (abst – 2015)
Inhibition of monoacylglycerol lipase mediates a cannabinoid 1-receptor dependent delay of kindling progression in mice. (Germany) (abst – 2015)
Withdrawal Seizures Seen In the Setting of Synthetic Cannabinoid Abuse. (USA) (abst – 2015)

Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. (USA) (abst – 2015)
Influence of arachidonyl-2′-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the anticonvulsant and acute side-effect potentials of clobazam, lacosamide and pregabalin in the maximal electroshock-induced seizure model and chimney test in mice. (Poland) (abst – 2015)
Zagaja/9afc69aba34a5995f8fc835b1b6a2808127c18f1 Long-term disease-modifying effect of the endocannabinoid agonist WIN55,212-2 in a rat model of audiogenic epilepsy. (Russia/ Netherlands) (abst – 2015)
JWH-018 impairs sensorimotor functions in mice. (Italy) (abst – 2015)
Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release. (Brazil) (abst – 2015)
Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR- 11. (Denmark) (abst – 2015)
Cannabis and Endocannabinoid Signaling in Epilepsy. (Hungary) (abst – 2015)
Polypharmacology Shakes Hands with Complex Aetiopathology. (UK/ Italy) (abst – 2015)
Convulsant effects of high efficacy synthetic cannabinoid JWH-018 in mice. (USA) (abst – 2015)
The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole- induced seizure severity in Wistar rats. (Brazil/ USA) (abst – 2015)
The Pharmacological Basis of Cannabis Therapy for Epilepsy. (USA) (full – 2016)
Cannabinoids for pediatric epilepsy? Up in smoke or real science? (USA) (full – 2016)
Transient increase of interleukin-1β after prolonged febrile seizures promotes adult epileptogenesis through long-lasting upregulating endocannabinoid signaling. (China/ Canada) (full – 2016)
Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome. (Spain/ Italy) (full – 2016)
ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. (Australia) (full – 2016)
CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. (Israel) (full – 2016)
-1311(16)00005-4/fulltext Case Series of Synthetic Cannabinoid Intoxication from One Toxicology Center. (USA) (full – 2016)
Fatty Acid Binding Proteins (FABPs) are Intracellular Carriers for Δ9- Tetrahydrocannabinol (THC) and Cannabidiol (CBD). (USA) (full – 2016)
Investigational new drugs for focal epilepsy. (UK) (full – 2016)
Is the medical use of cannabis a therapeutic option for children? (Canada) (full – 2016)
Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. (Spain) (full – 2016)
%5D=31745 Dentate cannabinoid-sensitive interneurons undergo unique and selective strengthening of mutual synaptic inhibition in experimental epilepsy. (USA/ China) (full – 2016)
Crucial Roles of the Endocannabinoid 2-Arachidonoylglycerol in the Suppression of Epileptic Seizures. (Japan) (full – 2016)
Turning Up the Heat on Endocannabinoid Signaling. (USA) (full – 2016)
Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol. (Brazil/ Italy) (full – 2016)
Medical Marijuana for Epilepsy? (USA) (full – 2016)
Investigational new drugs for focal epilepsy. (UK) (full – 2016)
Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol. (USA) (full – 2016)
Dentate cannabinoid-sensitive interneurons undergo unique and selective strengthening of mutual synaptic inhibition in experimental epilepsy. (USA/ China) (full – 2016)
Anticonvulsant activity of β-caryophyllene against pentylenetetrazol-induced seizures. (Brazil) (full – 2016)
Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation. (UK) (full – 2016)
From cannabis to cannabidiol to treat epilepsy, where are we? (Italy/ UK) (link to PDF– 2016)
Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents. (USA) (download – 2016)
Pharmacokinetic-pharmacodynamic influence of N-palmitoylethanolamine, arachidonyl- 2′-chloroethylamide and WIN 55,212-2 on the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. (Italy) (click “coreacuk” for download – 2016)
Effects of Marijuana on ictal and interictal EEG activity in idiopathic generalized epilepsy. (USA) (click “semanticscholar” for download – 2016)
Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure. (Iran) (click “therocus” for download – 2016) +of+Pilocarpine-Induced+Seizure.+++++++%22&btnG
Cannabis and epilepsy: An ancient treatment returns to the fore. (USA) (click “orvosikannabiz” for download – 2016)
Synthetic cannabinoids revealing adrenoleukodystrophy (Israel) (abst – 2016)
Adverse effects after the use of JWH-210 – a case series from the EU Spice II plus project (Germany) (abst – 2016)
Plant-Derived and Endogenous Cannabinoids in Epilepsy. (Italy) (abst – 2016)
Effect of JWH-250, JWH-073 and their interaction on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. (Italy) (abst – 2016)
Involvement of TRPV1 channels in the activity of the cannabinoid WIN 55,212-2 in an acute rat model of temporal lobe epilepsy. (Italy) (abst – 2016)
Cannabidiol and epilepsy: rationale and therapeutic potential. (Italy) (abst – 2016)
MEDICAL CANNABIS. (Israel) (abst – 2016)
CB1 Receptor Antagonism Prevents Long-Term Hyperexcitability after Head Injury by of Dynorphin-KOR System and mGluR5 in Rat Hippocampus. (China) (abst – 2016)
The cannabinoid receptor agonist WIN55.212 reduces consequences of status epilepticus in rats. (Russia/ Netherlands) (abst – 2016)
Marijuana use in adults admitted to a Canadian epilepsy monitoring unit. (Canada) (abst – 2016)
Endogenous cannabinoid system alterations and their role in epileptogenesis after brain injury in rat. (China) (abst – 2016)
Targeting brain and peripheral plasticity of the lipidome in acute kainic acid-induced epileptic seizures in mice via quantitative mass spectrometry. (Germany) (abst – 2016)
Synaptic Reorganization of the Perisomatic Inhibitory Network in Hippocampi of Temporal Lobe Epileptic Patients. (Hungary) (full – 2017)
Endocannabinoids: A Promising Impact for Traumatic Brain Injury. (USA) (full – 2017)
Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy. (Brazil) (full – 2017)
A Long-Term Treatment with Arachidonyl-2′-Chloroethylamide Combined with Valproate Increases Neurogenesis in a Mouse Pilocarpine Model of Epilepsy. (USA) (full – 2017)
Cannabinoids in Pediatrics. (USA) (full – 2017)
Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy? (Republic of Korea) (full – 2017)
Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid. (Israel) (full – 2017)
An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use (Australia) (full–2017)
Effects of arachidonyl-2′-chloroethylamide (ACEA) on the protective action of various antiepileptic drugs in the 6-Hz corneal stimulation model in mice. (Poland) (full – 2017)
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. (Germany) (full – 2017)
Addressing sufficiency of the CB1 receptor for endocannabinoid-mediated functions through conditional genetic rescue in forebrain GABAergic neurons. (Germany) (full – 2017)
The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity. (Italy/ Malta/ UK) (full – 2017)
Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with Refractory Epilepsy. (Mexico) (full – 2017)
The Role of BK Channels in Antiseizure Action of the CB1 Receptor Agonist ACEA in Maximal Electroshock and Pentylenetetrazole Models of Seizure in Mice. (Iran) (full – 2017)
Cannabinoid antagonist SLV326 induces convulsive seizures and changes in the interictal EEG in rats. (Netherlands/ Russia/ Germany) (full – 2017)
A spicy status: Synthetic cannabinoid (spice) use and new-onset refractory status epilepticus—A case report and review of the literature. (USA) (full – 2017)
Spice-y Kidney Failure: A Case Report and Systematic Review of Acute Kidney Injury Attributable to the Use of Synthetic Cannabis. (USA) (full – 2017)
Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans. (USA) (full – 2017)
Do Cannabinoids Confer Neuroprotection Against Epilepsy? An Overview. (Italy) (full – 2017)
Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? (Italy) (full – 2017)
Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study. (USA) (full – 2017)
Synthetic Pot: Not Your Grandfather’s Marijuana. (USA) (full – 2017)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. (USA) (full – 2017)
2003& Synthetic cannabinoid “Black Mamba” infidelity in patients presenting for emergency stabilization in Colorado: a P SCAN Cohort. (USA) (full – 2017)
Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet. (Italy/ USA) (full – 2017)
Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats. (USA) (full – 2017)
Cannabinoids for epilepsy: What do we know and where do we go? (UK/ Sweden) (full – 2017)
Medical Cannabinoids in Children and Adolescents: A Systematic Review. (USA) (full – 2017)
Fatty acid amide hydrolase inhibitor URB597 may protect against kainic acid-induced damage to hippocampal neurons: Dependence on the degree of injury. (Russia) (full – 2017)
Thermolytic degradation of synthetic cannabinoids: chemical exposures and pharmacological consequences. (USA/ Australia) (full – 2017)
Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. (UK/ USA) (full – 2017)
Cannabinoid receptor 1/2 double-knockout mice develop epilepsy. (USA/ Brazil) (full – 2017)
Chronic Inflammatory Pain Impairs mGluR5-Mediated Depolarization-Induced Suppression of Excitation in the Anterior Cingulate Cortex. (China) (full -2017)
Antiepileptic drugs in clinical development: differentiate or die? (Germany/ Italy) (link to PDF–2017)
Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon. (USA/ South Africa) (link to PDF– 2017) Cannabinoids in treatment-resistant epilepsy: A review. (Spain) (link to PDF–2017)
The Direct Actions of Cannabidiol and 2-Arachidonoyl Glycerol at GABAA Receptors (Australia) (link to PDF–2017)
Endocannabinoid-dependent protection against kainic acid-induced long-term alteration of brain oscillations in guinea pigs. (Russia) (link to PDF – 2017)
Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels. (Brazil) (click “unifalmgedubr” for download – 2017)
Neurological aspects of medical use of cannabidiol. (Italy) (click “coreacuk” for download – 2017)
Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification. (UK) (click “aaccjnls” for download – 2017)
Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature. (USA) (click “ucsfedu” for download – 2017) Neuronal nitric oxide synthase is involved in CB/TRPV1 signalling: Focus on control of hippocampal hyperexcitability. (Italy) (click “coreacuk” for download – 2017) Interaction between urethane and cannabinoid CB1 receptor agonist and antagonist in penicillin-induced epileptiform activity. (Turkey) (click “Free Full PDF” for download – 2017)
New-Onset Refractory Status Epilepticus Associated With the Use of Synthetic st Cannabinoids. (USA) (1 page – 2017)
Cannabis use in Epilepsy. Current situation in Argentina and abroad. (Argentina) (abst in English – 2017)
(download full in Spanish – 2017)
Historical perspective on the medical use of cannabis for epilepsy: Ancient times to the 1980s. (USA) (abst – 2017)
Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy. (USA) (abst – 2017)
Social factors in marijuana use for medical and recreational purposes. (USA) (abst – 2017)
Pharmacology of cannabinoids in the treatment of epilepsy. (USA) (abst – 2017)

Social correlates of health status, quality of life, and mood states in patients treated with cannabidiol for epilepsy. (USA) (abst – 2017)
Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? (Italy/ Spain/ Germany) (abst – 2017)
Cannabinoids as hippocampal network administrators. (USA) (abst – 2017)
Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. (UK/ Belgium) (abst – 2017)
Hudson/43414db17daf86cd4644238f6de9e27ea06f3ffe Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome. (USA) (abst – 2017)
Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP). (abst – 2017)
Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems. (Italy) (abst – 2017) Disseminated aspergillosis in an HIV-positive cannabis user taking steroid treatment (UK) (abst – 2017)
The potential role of cannabinoids in epilepsy treatment. (Italy) (abst – 2017)
Synthetic cannabinoid AM2201 induces seizures: Involvement of cannabinoid CB1 receptors and glutamatergic transmission. (Japan) (abst – 2017)
Simple and fast gas-chromatography mass spectrometry assay to assess delta 9- tetrahydrocannabinol and cannabidiol in dogs treated with medical cannabis for canine epilepsy. (Italy) (abst – 2017)
Efficacy and safety of cannabis for treating children with refractory epilepsy. (UK) (abst – 2017)
Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. (USA) (full – 2018)
Cannabidiol Regulates Long Term Potentiation Following Status Epilepticus: Mediation by Calcium Stores and Serotonin. (Israel) (full – 2018)
Positron emission tomography imaging of cerebral glucose metabolism and type 1 cannabinoid receptor availability during temporal lobe epileptogenesis in the amygdala kindling model in rhesus monkeys. (Belgium) (full – 2018)
Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. (Canada) (full – 2018) Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin. (Italy/ Netherlands) (full – 2018)
Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy. (Germany) (full – 2018)
Pediatric Death Due to Myocarditis After Exposure to Cannabis. (USA) (full – 2018)
Review of the neurological benefits of phytocannabinoids. (USA) (full – 2018)
Notes from the Field: Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol — Utah, 2017–2018. (USA) (full – 2018)
Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. (Australia) (full – 2018)
Cannabis for pediatric epilepsy: protocol for a living systematic review. (Canada) (full – 2018)
Evidence for THC versus CBD in cannabinoids. (Canada) (full – 2018)
Therapeutic Use of medicinal cannabis in difficult to manage epilepsy. (Australia) (full – 2018)
Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor. (Spain) (full – 2018)
Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. (Brazil) (full – 2018)
Cannabidiol for Treatment of Childhood Epilepsy-A Cross-Sectional Survey. (Germany/ Spain) (full – 2018)
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. (Brazil) (full – 2018)
The spatiotemporal expression changes of CB2R in the hippocampus of rats following pilocarpine-induced status epilepticus. (China) (full – 2018)
Interaction between warfarin and cannabis. (Denmark) (full – 2018)
Efficacy of cannabinoids in paediatric epilepsy. (New Zealand/ Australia) (full – 2018)
A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome. (Canada) (full – 2018)
Cannabis Therapeutics and the Future of Neurology. (USA) (full – 2018)
Epilepsy and Cannabis: A Literature Review. (Pakistan/ USA) (full – 2018)
Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. (Australia/ UK) (full – 2018)
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. (USA/ UK/ Spain) (full – 2018)
Cannabis in palliative care: current challenges and practical recommendations. (Canada/ USA) (full – 2018)
Erratum to cannabis in palliative care: current challenges and practical recommendations. (Canada/ USA) (erratum – 2018)
Cannabidiol for Epilepsy: New Hope on the Horizon? (USA) (full – 2018)
Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol; Corresponding Change to Permit Requirements. Final order. (USA) (full – 2018)
certain-fda-approved-drugs-containing Cannabis Oil in an Irish Children’s Critical Care Unit. (Ireland) (full – 2018)
Treatment of infantile spasms. (USA) (full – 2018)
Plants come to mind: phytocannabinoids, endocannabinoids and the control of seizures. (USA) (full – 2018)
Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study. (Israel) (full – 2018)
Simultaneous lipidomic and transcriptomic profiling in mouse brain punches of acute epileptic seizure model compared to controls. (Germany/ Netherlands) (full – 2018)
Neuroprotective Action of the CB1/2 Receptor Agonist, WIN 55,212-2, against DMSO but Not Phenobarbital-Induced Neurotoxicity in Immature Rats. (USA) (full – 2018)
Anticonvulsant and Neuroprotective Effects of Cannabidiol During the Juvenile Period. (USA) (full – 2018)
Cannabis for the treatment of paediatric epilepsy? An update for Canadian paediatricians (Canada/ Israel) (full – 2018)
Pharmacological characterization of the cannabinoid receptor 2 agonist, β-caryophyllene on seizure models in mice. (Brazil/ Bulgaria) (full – 2018)
Coma, Seizures, Atrioventricular Block, and Hypoglycemia in an ADB-FUBINACA Body-Packer. (USA) (full – 2018)
Cannabis and epilepsy. (UK/ Ireland) (full – 2018)
Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities. (USA/ India/ Brazil) (link to PDF – 2018)
Cannabis for the Treatment of Epilepsy: an Update. (USA) (link to PDF – 2018)
Practical considerations in medical cannabis administration and dosing. (Canada/ Czech Republic) (link to PDF – 2018)
Species-specific susceptibility to cannabis-induced convulsions. (UK/ Ireland/ USA) (download– 2018) Species-specific susceptibility to cannabis-induced convulsions The Path to the First FDA-Approved Cannabis-Derived Treatment and What Comes Next (USA) (link to download – article-2018)
Cannabinoids: just like any other medication? (UK) (article – 2018)
Safety of cannabidiol prescribed for children with refractory epilepsy. (Italy) (letter – 2018)
Cannabis, cannabis everywhere: UK to review medical cannabis policy as Canada plans imminent legalisation for all uses. (UK) st (1 page of editorial – 2018)
Arvanil, olvanil, AM 1172 and LY 2183240 (various cannabinoid CB1 receptor agonists) increase the threshold for maximal electroshock-induced seizures in mice. (Poland) (abst – 2018) Medical cannabis: “restrictive” guidance lets patients down, say campaigners. (UK) (abst – 2018)
Intoxication From Accidental Marijuana Ingestion in Pediatric Patients: What May Lie Ahead. (USA) (abst – 2018)
Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signaling. (Japan) (abst – 2018)
Endocannabinoid CB1 receptors are involved in antiepileptogenic effect of low frequency electrical stimulation during perforant path kindling in rats. (Iran) (abst – 2018)
Investigational cannabinoids in seizure disorders, what have we learned thus far? (Serbia) (abst – 2018)
TRPV1 mediates the anticonvulsant effects of acetaminophen in mice. (Japan) (abst – 2018)
Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis. (Italy) (abst – 2018)
Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model. (Spain) (abst – 2018)
Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders. (Spain/ Italy) (abst – 2018)
Inhibitions of anandamide transport and FAAH synthesis decrease apoptosis and oxidative stress through inhibition of TRPV1 channel in an in vitro seizure model. (Turkey) (abst – 2018) Acute foot-shock stress decreased seizure susceptibility against pentylenetetrazole- induced seizures in mice: Interaction between endogenous opioids and cannabinoids. (Iran/ Canada/ USA) (abst – 2018)
Marijuana’s Effects on Brain Structure and Function: What Do We Know and What Should We Do? A Brief Review and Commentary. (USA) (abst – 2018)
Medical cannabis: A needs analysis for people with epilepsy. (Australia) (abst – 2018)
The US Food and Drug Administration’s Authorization of the First Cannabis-Derived Pharmaceutical – Are We Out of the Haze? (USA) (abst – 2018)
The level of evidence of medical marijuana use for treating disabilities: a scoping review. (USA) (abst – 2018)
Simultaneous quantification of thirteen cannabinoids and metabolites in human plasma by liquid chromatography tandem mass spectrometry in adult epilepsy patients. (USA) (abst – 2018) Cannabis-based products for pediatric epilepsy: A systematic review. (Canada) (full – 2019)
The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No “Strain,” No Gain. (Czech Republic) (full – 2019)
US Veterinarians’ Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions. (USA) (full – 2019)
Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy? (USA) (full – 2019)
Spontaneous, anecdotal, retrospective, open-label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan). (Italy) (full – 2019)
Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects. (USA) (full – 2019)
Review of the many faces of synthetic cannabinoid toxicities. (USA) (full – 2019)
Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. (Canada) (full – 2019)
Medicinal use of cannabis based products and cannabinoids. (UK) (full – 2019)

Single and Synergistic Effects of Cannabidiol and Δ-9-Tetrahydrocannabinol on Zebrafish Models of Neuro-Hyperactivity. (Canada) (full – 2019)
Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. (Italy) (full – 2019)
Why I campaign for children like my son Alfie Dingley to be able to get medical cannabis. (UK) (full – 2019)
Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy. (USA/ Belgium) (full – 2019)
Synthetic, non-intoxicating 8,9-dihydrocannabidiol for the mitigation of seizures. (USA/ UK) (full – 2019)
Metabolomics and Communication Skills Development in Children; Evidence from the Ages and Stages Questionnaire. (USA) (full – 2019)
The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. (Israel) (full – 2019)
Should more patients be offered treatment with cannabinoids? (Norway) (full – 2019)
Dravet Syndrome: An Overview. (USA) (full – 2019)
Cannabidiol reduces seizures following CNS infection with Theiler’s murine encephalomyelitis virus. (USA) (full – 2019)
Ontogeny and programming of the fetal temporal cortical endocannabinoid system by moderate maternal nutrient reduction in baboons (Papio spp.). (USA) (full – 2019)
Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. (Australia) (full – 2019)
American Epilepsy Society (AES): Written Comments to Norman E. “Ned” Sharpless, MD, Acting Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS): on Docket ID# FDA-2019-N- 1482, Scientific Data and Information about Products Containing Cannabis or Cannabis- Derived Compounds; Public Hearing; Request for Comments: Submitted on: July 16, 2019. (USA) (full – 2019) Cannabidiol. (USA) (full – 2019)

A preliminary study of the effects of cannabidiol (CBD) on brain structure in patients with epilepsy. (USA) (full – 2019)
The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids. (Australia) (full – 2019)
Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use. (Brazil) (full – 2019)
Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice. (USA) (full – 2019)
Cannabis-based medicinal products. (UK) (full – 2019)
Cannabis Influences the Putative Cytokines-Related Pathway of Epilepsy among Egyptian Epileptic Patients. (Egypt/ Germany) (link to PDF – 2019)
Investigating the Therapeutic Mechanism of Cannabidiol in a Human Induced Pluripotent Stem Cell (iPSC)-Based Cellular Model of Dravet Syndrome. (USA) (download – 2019)
Crossing the Line: Care of a Pediatric Patient with Intractable Seizures and Severe Neuropathic Pain in Absence of Access to Medical Marijuana. (USA) (link to download – 2019)
Why medical cannabis is still out of patients’ reach-an essay by David Nutt. (UK) (click “drugscience” for download – 2019)
Cannabis-based treatments as an alternative remedy for epilepsy. (USA) (article – 2019)

Medical cannabis: no NHS patients have benefited from law change, say campaigners (UK) (1st page – 2019)
The Surprising Reach of FDA Regulation of Cannabis, Even After Descheduling (USA) (abst–2019)
Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes. (USA) (abst–2019)
Cannabinoid therapy in epilepsy. (USA) (abst – 2019)
A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential. (USA) (abst – 2019)
Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder. (Australia/ USA) (abst – 2019)
Improving post-hypoxic myoclonus using cannabidiol. (USA) (abst – 2019)
Reclassifying cannabis based drugs has not made accessing them easier, MPs hear. (UK) (abst – 2019)
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. (USA) (abst – 2019)
Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. (Italy/ Austria) (abst – 2019)
Disposition of oral delta-9 tetrahydrocannabinol (THC) in children receiving cannabis extracts for epilepsy. (USA) (abst – 2019)
Medical Marijuana in the Pediatric Population With Epilepsy-What You Should Know. (USA) (abst – 2019)
Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. (USA) (abst – 2019)
Marijuana use among patients with epilepsy at a tertiary care center. (USA) (abst – 2019)
Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. (Italy) (abst – 2019)
Knowledge, expectations and fears of cannabis use of epilepsy patients at a tertiary epilepsy center. (Germany) (abst – 2019)
Drug–drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures. (USA) (abst – 2019)
Early endocannabinoid system activation attenuates behavioral impairments induced by initial impact but does not prevent epileptogenesis in lithium–pilocarpine status epilepticus model. (Russia) (abst – 2019)
Piperidine and piperazine inhibitors of fatty acid amide hydrolase targeting excitotoxic pathology. (USA) (abst – 2019)
Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency. (Netherlands) (abst – 2019)
Cannabinoids, hippocampal excitability and efficacy for the treatment of epilepsy. (Israel) (abst – 2019)
Marijuana use among patients with epilepsy at a tertiary care center. (USA) (abst – 2019)
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome. (Australia) (abst – 2019)
Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. (Italy/ Sweden) (abst – 2019)
Medicinal cannabis in Latin America: History, current state of regulation, and the role of the pharmacist in a new clinical experience with cannabidiol oil. (Argentina) (abst–2019)
Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. (USA) (abst – 2019)
Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment- resistant epilepsy: Systematic review and meta-analysis. (Brazil) (abst – 2019)
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders (USA/ Italy) (abst–2019)
Epileptic Spikes in EEG and Migraine Attacks in the Course of Cannabis Withdrawal: A Case Report. (Germany) (abst – 2019)
Reduced cannabinoid 2 receptor activity increases susceptibility to induced seizures in mice. (USA) (abst – 2019)
Cannabinoids for drug-resistant seizures in a critically ill patient-Case report and literature review. (Australia) (abst – 2019)
The use of medical grade cannabis in Italy for drug-resistant epilepsy: a case series. (Italy) (abst – 2019)
A perspective on cannabinoids for treating epilepsy: do they really change the landscape? (UK) (abst – 2019)
Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: A multicenter phase-2 study. (USA/ Belgium) (abst – 2019)
Cannabis-based medicines and the perioperative physician. (Canada/ UK) (abst – 2019)
Cannabinoids and the expanded endocannabinoid system in neurological disorders. (Italy/ Canada) (abst – 2019)
Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment. (Brazil) (abst–2019)
Potential role of cannabidiol for seizure control in a patient with recurrent glioma (Australia) (abst – 2019)

The cannabidiol conundrum potential benefits and risks of cannabidiol products for children. (USA) (abst – 2019)
Synthetic cannabinoid receptor agonists-induced recurrent seizure in elderly patient. (USA) (abst – 2019)
Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission? (Italy/ Netherlands) (full – 2020)
Medical Cannabis for Intractable Epilepsy in Childhood: A Review. (Israel) (link to download – 2020)
Medical Cannabis in Children. (Israel) (link to download – 2020)
Cannabis-based products for pediatric epilepsy: An updated systematic review. (Canada) (abst – 2020)
The Use of Cannabis as a Treatment for Epilepsy in Adult Patients: Are Side Effects a Limitation of Use? (Canada/ Colombia) (abst – 2020)
The Endocannabinoid System and Synthetic Cannabinoids in Preclinical Models of Seizure and Epilepsy. (Canada) (abst – 2020)
A North American History of Cannabis Use in the Treatment of Epilepsy (Canada) (abst–2020)
Cannabis for Pediatric Epilepsy. (Canada/ USA) (abst – 2020)
The cannabidiol conundrum: potential benefits and risks of cannabidiol products for children. (USA) (abst – 2020)
The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials. (France/ USA) (abst – 2020)
The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights. (Brazil) (abst – 2020)
The other side of the leaf: Seizures associated with synthetic cannabinoid use. (Australia) (abst – 2020)

Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. (Iran/ UK) (full – 2016)
Cannabinoid receptor agonism suppresses tremor, cognition disturbances and anxiety-like behaviors in a rat model of essential tremor. (Iran/ UK) (click “readingacuk” for download – 2016)
Effect of marijuana on Essential Tremor: A case report. (USA) (abst – 2016)

Bioethical analysis to the therapeutic use of Cannabis: Integrative review. (Brazil) (abst – 2017)
Silva/ad2d2a17b489a983063db23cd856a3d5ea1f5ccb Ethical Issues Arising from Marijuana Use by Nursing Mothers in a Changing Legal and Cultural Context. (USA) (abst – 2018)
Ethical issues in medical cannabis use. (Israel) (abst – 2018)
Cannabis money opens new opportunities, and ethical dilemmas, for medical research. (Canada) (full – 2019)
Cannabis for Inflammatory Bowel Diseases: Should We Follow the Wisdom of the Crowd? (Israel) (full – 2019)
Ethical Implications for Providers Regarding Cannabis Use in Children With Autism Spectrum Disorders. (USA) (click “aappublicationsorg” for full – 2019)

A runner’s high depends on cannabinoid receptors in mice. (Germany) (full – 2015)
Cannabinoid Receptor 1 and Acute Resistance Exercise – In vivo and In vitro Studies in Human Skeletal Muscle. (Finland/ France/ China) (abst – 2015)
115000650 Deletion of G-protein coupled receptor 55 promotes obesity by reducing physical activity. (USA/ China) (abst – 2015)
Cannabis and Exercise Science: A Commentary on Existing Studies and Suggestions for Future Directions (USA) (abst–2015)
Changes in IGF-I, urinary free cortisol and adipokines during dronabinol therapy in anorexia nervosa: Results from a randomised, controlled trial. (Denmark) (abst – 2015)
Neuromodulation of Aerobic Exercise—A Review (Netherlands/ Germany) (full–2016)
Sleep restriction alters plasma endocannabinoids concentrations before but not after exercise in humans. (Sweden/ Italy/ Germany) (full – 2016)
Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids. (USA/ China) (full – 2016)
Circulating levels of endocannabinoids respond acutely to voluntary exercise, are altered in mice selectively bred for high voluntary wheel running, and differ between the sexes. (USA) (full – 2016)
Restricted vs. unrestricted wheel running in mice: Effects on brain, behavior and endocannabinoids. (Germany) (link to PDF – 2016)
Effects of chronic exercise on the endocannabinoid system in Wistar rats with high-fat diet-induced obesity. (France/ Italy) (abst – 2016)
Exercise deprivation increases negative mood in exercise-addicted subjects and modifies their biochemical markers. (Brazil) (abst – 2016)
The role of exercise training and the endocannabinoid system in atherosclerotic plaque burden and composition in Apo-E-deficient mice. (Greece) (full – 2017)

Anxious behavior induces elevated hippocampal Cb2 Receptor gene expression. (USA) (full – 2017)
Running Out of Options: Rhabdomyolysis Associated with Cannabis Hyperemesis Syndrome (USA) (full–2017)
Cannabinoid CB1/CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity-based anorexia. (Italy) (full – 2017)
Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? (USA) (full – 2017)
Exercise versus targeting of endocannabinoid system for atheromatic plaque stabilization. Opposing or complementary roles? (Greece) (link to PDF – 2017)
Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat. (USA) (link to PDF–2017)
Endocannabinoid and Opioid System Interactions in Exercise-Induced Hypoalgesia. (USA) (link to PDF – 2017)
Psychobiological Responses to Aerobic Exercise in Individuals With Posttraumatic Stress Disorder. (USA) (link to PDF– 2017)
Endocannabinoid and Mood Responses to Exercise in Adults with Varying Activity Levels. (USA) (link to PDF – 2017)
Cannabis: Exercise performance and sport. A systematic review. (Australia) (link to PDF – 2017)
Exercise training and high-fat diet elicit endocannabinoid system modifications in the rat hypothalamus and hippocampus. (France/ Italy) (link to PDF – 2017)
fat_diet_elicit_endocannabinoid_system_modifications_in_the_rat_hypothalamus_and_hippocampus Voluntary exercise improves cognitive deficits in female dominant-negative DISC1 transgenic mouse model of neuropsychiatric disorders. (Israel) (click “Alternate Sources” then “46cec243-71bb-” for download – 2017)
AMPK contributes to aerobic exercise-induced antinociception downstream of endocannabinoids. (Germany) (abst – 2017)
Moderate and vigorous physical activity patterns among marijuana users: Results from the 2007-2014 National Health and Nutrition Examination Surveys. (USA) (abst – 2017)
The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. (USA) (full – 2018)
Effects of exercise on experimentally manipulated craving for cannabis: A preliminary study. (USA) (full – 2018)
A Behavioral Economic Analysis of Marijuana and Other Drug Use Among Heavy Drinking Young Adults. (USA) (full – 2018)
Aerobic Fitness Level Moderates the Association Between Cannabis Use and Executive Functioning and Psychomotor Speed Following Abstinence in Adolescents and Young Adults. (USA) (full – 2018)
Endocannabinoids, exercise, pain, and a path to health with aging. (USA) (full – 2018)
Endogenous systems involved in exercise-induced analgesia. (Brazil) (full – 2018)
Seasonal Changes in Endocannabinoid Concentrations between Active and Hibernating Marmots (Marmota flaviventris). (USA) (full – 2018) Effect of Vaporized Cannabis on Exertional Breathlessness and Exercise Endurance in Advanced COPD: A Randomized Controlled Trial. (Canada) (full– 2018)
The New Runner’s High? Examining Relationships Between Cannabis Use and Exercise Behavior in States With Legalized Cannabis. (USA) (full – 2019)
The Endocannabinoid System as a Potential Mechanism through which Exercise Influences Episodic Memory Function. (China/ USA) (full – 2019)
The motivation for exercise over palatable food is dictated by cannabinoid type-1 receptors. (France/ Spain/ Italy) (full – 2019)
Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome. (Canada/ Italy) (full – 2019)
Beyond the Activity-Based Anorexia Model: Reinforcing Values of Exercise and Feeding Examined in Stressed Adolescent Male and Female Mice. (France) (full – 2019)
An Analysis of Endocannabinoid Concentrations and Mood Following Singing and Exercise in Healthy Volunteers. (UK) (full – 2019)
Chronic exercise modulates the cellular immunity and its cannabinoid receptors expression. (Mexico) (full – 2019)
Serum Endocannabinoid and Mood Changes after Exercise in Major Depressive Disorder. (USA) (full – 2019)
[EXPRESS] Altered relationship between anandamide and glutamate in circulation after 30 minutes of arm cycling: A comparison of chronic pain subject with healthy controls. (Sweden) (link to PDF – 2019)
Loss of exercise- and stress-induced increases in circulating 2-arachidonoylglycerol concentrations in adults with chronic PTSD. (USA) (link to download – 2019) Loss of exercise- and stress-induced increases in circulating 2 … Is Cannabis Use Associated with Sedentary Behavior during Leisure Time? A Study in Canada, 2011-2012. (Canada) (abst – 2019)
Performance and Health-Related Characteristics of Physically Active Males Using Marijuana. (USA) (abst – 2019)
Diet, endocannabinoids, and health. (USA) (abst – 2019)
Chronic aerobic exercise: Lack of effect on brain CB1 receptor levels in adult rats. (USA) (abst – 2019)
Cannabis use and leisure-time sedentary behavior among 94,035 adolescents aged 12– 15 years from 24 low- and middle-income countries. (Belgium/ Australia/ UK/ Canada/ Spain) (abst – 2019)
Involvement of Spinal Cannabinoid CB2 Receptors in Exercise-Induced Antinociception. (Brazil) (abst – 2019)
Low intensity blood flow restriction exercise: Rationale for a hypoalgesia effect. (UK) (abst – 2019)
Antinociceptive effects of treadmill exercise in a rat model of Parkinson’s disease: the role of cannabinoid and opioid receptors. (Brazil) (abst – 2019)
Cannabis use and physical activity among 89,777 adolescents aged 12-15 years from 21 low- and middle-income countries. (Canada/ UK/ Belgium/ Australia/ Italy/ Spain) (abst – 2019)
Psychological and endocannabinoid responses to aerobic exercise in substance use disorder patients. (USA) (abst – 2019)
Anandamide Is Related to Clinical and Cardiorespiratory Benefits of Aerobic Exercise Training in Migraine Patients: A Randomized Controlled Clinical Trial. (Brazil) (abst – 2019)
Treadmill exercise improves LPS-induced memory impairments via endocannabinoid receptors and cyclooxygenase enzymes. (Iran) (abst – 2019) 


Updated 20 March 2020